Coming soon.  

Coming soon.  

Coming soon.  

 Coming soon. 

We would like to update you on the change of the CEEGOG residence. The proposal for the new place of residence was approved by all participants at the CEEGOG meeting in December 2016. Starting June, 2017, the Association resides in the city of Prague, Na Folimance 2155/15, Praha 2 – Vinohrady.

CEEGOG was represented by Roman Kocian in the meeting. Participants were welcomed by Prof. Ignace Vergote, Cristiana Sessa, Antonio Casado.
First, we discussed finalisation of umbrella trial synopsis for the following proposals: Alejandro Perez Fidalgo for recurrent endometrial cancer, Ros Glasspool on the Umbrella trial in platinum-refractory recurrent ovarian cancer, Nicole Concin on the Umbrella trial in Non-HRD recurrent ovarian cancer, Ronnie Shapira on the Umbrella trial in recurrent cervical cancer. Cristiana Sessa presented a new trial proposal on behalf of Viola Heinzelmann, President of Gyn working group of the SAKK, on a Phase II study with the MELK inhibitor in platinum resistant OvCa.
Second, funding strategies were discussed: e.g. if one trial can be realised in one country, other countries will try to join via self-organisation of funding within their country for this specific trial (e.g. by contacting the industry representative in the specific country or by applying for academic funding at national research bodies).
Third, the group reviewed the list of centres from each country for ENGOT Ph I/II network received from the national trial groups. The group suggested to abolish the limitation in the number of centres. The most important factor for a centre to be nominated should be experience in early Phase clinical trial performance in gynaecological malignancies and interest in doing so (feasibility questionnaire will be created and send out via ENGOT office to national trial groups).

Finally, there is an upcoming meeting with the industry in October 2017, where Ph1/Ph2 representatives will present their trial proposals. In relation to that, prof. Vergote spoke about the existing ENGOT rules on the cooperation with the industry

I am pleased to announce that CEEGOG will be represented in the third series of Gynaecological Cancer Academy workshops by Dr. Vít Weinberger from the University Hospital Brno (Czech Republic).

On March 3 - 4, 2017, a meeting of representatives of the twenty national trial groups was held in Spanish Valencia. CEEGOG was represented by its Chairman Prof. David Cibula and the administrative manager Mrs. Ivana Nohová.  

The Engot Admin meeting focused on EU regulations, the GCP amendment, trial budgeting, the ENGOT welcome package, the new ENGOT website, and on the summary of the strategic meeting held in Copenhagen in October 2016.
The main topic of the ENGOT assembly meeting involved trial activities and the status of collaboration as usual. The CEEGOG/ENGOT trials, i.e. the SENTIX trial and the ABRAX trial were disscussed, too. There is big interest to join the ABRAX study within ENGOT groups. It was agreed to send out the ABRAX protocol to all ENGOT groups.
The status of collaboration was presented and the integration of ENGOTgroups with less activity was also discussed. Altough being a relatively small and new group, CEEGOG is ranked among the active groups within ENGOT thanks to their Chairman´s activity and CEEGOG centers interest to participate in ENGOT trials. Moreover, Prof. David Cibula delivered again a presentation on the new project idea – SEDLIS 2020.
Other topics of discussion were as follows: rare tumors, how to manage competition with pharma and GOG, TR activity and tumor bank, finances and website, update on publication rules, GCA workshops, PhaseI/II trials and EVA privileged partnership.
For more information, you are welcome to contact the CEEGOG office.

Ovarian cancer study
Women with relapsed ovarian cancer can take part in SOLO3, a clinical study for ovarian cancer, supported by AstraZeneca, to help scientists find better treatments for this disease.  This page provides information about the SOLO3 clinical trial.
A clinical study of olaparib in women who:

Have previously been diagnosed and treated for ovarian cancer, peritoneal cancer, and/or fallopian tube cancer and their disease has come back. 

Have an inherited BRCA mutation. In case of an unknown BRCA status, patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease >6 months (>/=183 days) after completion of their last platinum therapy. Note: The BRCA test is covered by the sponsor.

Have completed at least two courses of platinum-based chemotherapy, and finished the last course at least six months ago.  Platinum agents are carboplatin, cisplatin, and oxalaplatin
 
Have a tumor that has shrunk or disappeared following their last course of platinum-based chemotherapy
 
For information on SOLO3 participating study locations for referrals, please visit www.astrazenecaclinicaltrials.com and enter ‘SOLO3’ in the search box.
 

We would like to express our thanks for your participation in the CEEGOG meeting held in Prague on December 9, 2016. It is our pleasure to invite the 9 new centers for cooperation. Currently  CEEGOG is composed of 39 centres from 8 countries – the Czech Republic, Slovakia, Poland, Slovenia, Ukraine, Hungary, Belarus, Georgia.

  1. CEEGOG meeting in Prague on December 9, 2016
  2. ENGOT meeting in Malmö, October 6 – 7, 2016
  3. Gynaecological Cancer Academy (GCA) on September 30, 2016
  4. View of all clinical trials
  5. Fourth country in CEEGOG , September 2016
  6. SENTIX trial, July 2016
  7. Change of the CEEGOG residence, July 2016
  8. Gynaecological Cancer Academy (GCA), May 13 – 14, 2016
  9. HE4-FU-OVCA trial, April 2016
  10. CEEGOG meeting in Prague on April 20, 2016